Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04951700 · ClinicalTrials.gov registry record
Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia
A clinical trial of Schizophrenia and Aging, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- 194
- Enrollment target
- 1
- Study location
NCT04951700 is a study of Schizophrenia and Aging that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 194 participants, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04951700, a study of Schizophrenia and Aging, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 194 participants
- Enrollment target
- 1
- Study location
Study Summary
The 2020 NIMH Strategic Plan for Research calls for investigations targeting neurobiology of mental illness across the lifespan. Growing evidence suggests that lifespan neurobiology of schizophrenia (SZ) incorporates two distinct dimensions: aging and disease course. However, their clinical correlates, associated biomarker trajectories, and implications for treatment are unknown. This study will investigate differential aspects of SZ neurobiology captured by aging and disease course, in order to develop specific biomarkers which may offer actionable targets for SZ stage-dependent intervention. The study is predicated on a novel mechanistic Model of SZ Trajectories across the Adult Lifespan, positing distinct biological fingerprints within the anterior limbic system for aging and disease course in SZ: (1) alterations in the circuit's function and structure that occur earlier in the lifespan and are larger in magnitude than the alterations expected with normal aging (accelerated aging dimension); and (2) regionally-specific anterior limbic "hyperactivity" in early SZ, with a subsequent transformation into "hypoactivity" in advanced SZ (disease course dimension). In a sample of SZ and matched healthy controls (n=168, 84/group) aged 18-75 years the investigators will ascertain a broad panel of biomarkers \[via multimodal brain imaging: optimized 1H-MRS, high-resolution task-based fMRI, perfusion (Vascular Space Occupancy) and structural MRI\], along with comprehensive cognitive and clinical assessments. All measures will be acquired at baseline and repeated at 2-year longitudinal follow-up. Using cutting-edge computational approaches, the study will examine (i) effects of aging and SZ course on anterior limbic system biomarkers; (ii) lifespan trajectories for different biomarkers; (iii) patterns of limbic system biomarkers in age- and SZ course-based subgroups (e.g., Younger vs. Older, Early-Course vs. Advanced SZ), as well as in data-driven subgroups (e.g., those with
Conditions Studied
Interventions
- OTHER Other
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2027-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04951700
The ClinicalTrials.gov registry entry for NCT04951700 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (11% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Other is the first listed.
NCT04951700 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04951700 about?
NCT04951700 is a clinical study titled "Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia". The 2020 NIMH Strategic Plan for Research calls for investigations targeting neurobiology of mental illness across the lifespan. Growing evidence suggests that lifespan neurobiology of schizophrenia (SZ) incorporates two distinct dimensions: aging and disease course. However, their clinical correlat...
What is the current status of trial NCT04951700?
This trial is currently active not recruiting. The enrollment target is 194 participants. The study started on 2021-07-01. Estimated completion is 2027-04-30.
What conditions does trial NCT04951700 study?
This clinical trial studies the following conditions: Schizophrenia, Aging, Cognitive Dysfunction, Neuroimaging, Biomarker.
What interventions are being tested in trial NCT04951700?
The interventions under investigation include: Other (OTHER).
Who is sponsoring clinical trial NCT04951700?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04951700 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.